Bioray Biotech Co., Ltd (TPEX:7561)
Taiwan · Delayed Price · Currency is TWD 19.60
-0.15 (-0.76%)
May 8, 2026, 1:30 PM CST
Bioray Biotech Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 32.25 | 1 | -11.56 | 0.5 | -7.19 |
Depreciation & Amortization | 23.59 | 24.47 | 24.48 | 21.87 | 18.83 |
Other Amortization | - | 0.51 | 0.52 | 0.36 | 0.25 |
Loss (Gain) From Sale of Assets | - | 0.05 | -0.2 | -0.18 | - |
Asset Writedown & Restructuring Costs | - | - | 1.3 | - | - |
Stock-Based Compensation | - | - | - | 0.02 | - |
Provision & Write-off of Bad Debts | -0.11 | 0.44 | -0.01 | 0.08 | - |
Other Operating Activities | 10.05 | 1.79 | -0.27 | 1.8 | 1.62 |
Change in Accounts Receivable | 13.42 | -4.2 | -0.56 | -5.96 | -13.66 |
Change in Inventory | -16.31 | 9.18 | -4.12 | -6.44 | 2.82 |
Change in Accounts Payable | -1.65 | -4.96 | -3.15 | 1.21 | 4.75 |
Change in Unearned Revenue | -6.38 | 4.97 | -2.52 | -2.98 | 1.49 |
Change in Other Net Operating Assets | 16.77 | -16.6 | -4.67 | -7.8 | -0.07 |
Operating Cash Flow | 71.64 | 16.65 | -0.76 | 2.48 | 8.83 |
Operating Cash Flow Growth | 330.16% | - | - | -71.93% | 427.42% |
Capital Expenditures | -0.37 | -3.22 | -10.02 | -59.64 | -14.98 |
Sale of Property, Plant & Equipment | 0.42 | 50.56 | 0.2 | 0.36 | 0.55 |
Cash Acquisitions | - | - | -3.54 | - | - |
Sale (Purchase) of Intangibles | -0.05 | -0.08 | -0.16 | -0.75 | -0.56 |
Other Investing Activities | 0.72 | 6.46 | 0.97 | 0.39 | -4.8 |
Investing Cash Flow | 0.73 | 53.72 | -12.55 | -59.63 | -19.79 |
Short-Term Debt Issued | - | - | 10 | 15 | 15 |
Long-Term Debt Issued | - | 55 | - | - | - |
Total Debt Issued | - | 55 | 10 | 15 | 15 |
Short-Term Debt Repaid | - | - | -25 | -25 | -17.2 |
Long-Term Debt Repaid | -45.75 | -29.7 | -7.59 | -6.42 | -5.95 |
Total Debt Repaid | -45.75 | -29.7 | -32.59 | -31.42 | -23.15 |
Net Debt Issued (Repaid) | -45.75 | 25.3 | -22.59 | -16.42 | -8.15 |
Repurchase of Common Stock | - | -14.17 | - | - | - |
Common Dividends Paid | - | - | -6.02 | - | - |
Other Financing Activities | 0.09 | -0.32 | -0.13 | 86.34 | -0.48 |
Financing Cash Flow | -45.66 | 10.82 | -28.73 | 69.92 | -8.64 |
Foreign Exchange Rate Adjustments | - | - | 0 | -0.01 | 0.01 |
Net Cash Flow | 26.71 | 81.19 | -42.04 | 12.75 | -19.59 |
Free Cash Flow | 71.27 | 13.43 | -10.78 | -57.16 | -6.15 |
Free Cash Flow Growth | 430.67% | - | - | - | - |
Free Cash Flow Margin | 32.00% | 6.66% | -5.62% | -29.99% | -4.15% |
Free Cash Flow Per Share | 2.41 | 0.45 | -0.36 | -2.04 | -0.23 |
Cash Interest Paid | - | 0.32 | 0.13 | 0.33 | 0.95 |
Cash Income Tax Paid | - | -0.2 | 0.03 | -1.17 | 0.36 |
Levered Free Cash Flow | 59.08 | 7.72 | -12.81 | -60.67 | -5.78 |
Unlevered Free Cash Flow | 59.49 | 8.55 | -11.98 | -59.81 | -5.18 |
Change in Working Capital | 5.85 | -11.61 | -15.02 | -21.97 | -4.68 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.